Halozyme Therapeutics Appoints Former J&J Executive Darren Snellgrove as CFO

On April 30, 2026, Halozyme Therapeutics announced the appointment of Darren Snellgrove as Chief Financial Officer, effective June 8, 2026. Mr. Snellgrove joins Halozyme after a 27-year career at Johnson & Johnson, where he most recently served as Vice President, Investor Relations and previously as CFO of the Pharmaceutical sector. He succeeds Interim CFO David Ramsay, who will transition into an advisory role to assist with the leadership change. Under the terms of his employment, Mr. Snellgrove will receive an annual base salary of $670,000 and a $350,000 sign-on bonus. His compensation package includes a significant equity component: $3.2 million in restricted stock units (RSUs) to make him whole for forfeited J&J equity, and $4.0 million in stock options. Starting in 2027, he will be eligible for annual long-term incentive awards with a minimum grant date value of $4.0 million. Mr. Snellgrove will report directly to President and CEO Helen Torley and will oversee financial operations, capital allocation, and investor relations.